Verint Systems Inc. (NASDAQ:VRNT) last session’s volume of 0.62 million shares was higher than its average volume of 0.46 million shares. The stock, after opening at $39.7, hit $38.8 through the close by scoring -2.39%.Verint Systems Inc. (VRNT) Analyst Opinion
Verint Systems Inc. has a consensus outperform rating from 8 Wall Street analysts, and the number of shares currently sold short amount to at least 2.81% of shares outstanding. The stock sank -3.24% last month and is up 10.07 this year. Wall Street is only getting more bullish on the stock, with 5 of analysts who cover VRNT having a buy-equivalent rating. Analysts have placed a $43.83 price target on Verint Systems Inc., suggesting a 12.96% gain from recent close. It’s currently trading about -13.2% below its 52-week high.Verint Systems Inc. Earnings Surprise
Verint Systems Inc. (VRNT) surprised the stock market in its last reported earnings when it earned $0.9 a piece versus the consensus-estimated $0.86. Its revenue totaled $293.89 million up 13.02% from the previous quarter. Expect increased sales in the current quarter as well. As per the consensus estimate, the company’s year-on-year revenue growth is expected to be at 5.82% during the period. Last year, it had about $245.42 million of revenue.
This stock (VRNT) is ahead of its 52-week low with 23.45%. Its last month’s stock price volatility remained 2.5% which for the week stands at 2.41%. The share price has moved backward from its 20 days moving average, trading at a distance of -5.71% and stays -1.12% away from its 50 days moving average. Over the last five days, shares have faced -5.02% losses and now is up 5.4% since hitting its 200-day moving average of $37.62. Verint Systems Inc. (VRNT) has made its way to a 12-month gain of 9.05%.
Turning to Repros Therapeutics Inc. (NASDAQ:RPRX), its shares were trading at $1.09 a gain of $0.06, on the trading floor. The stock, after opening at $1.06, touched a high of $1.12 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.5. Repros Therapeutics Inc. has 1 buy ratings, 0 holds and 0 sells even after the stock tumbled -68.68% from its high of $3.45 to a $27.7 million market value through last close.Repros Therapeutics Inc. (RPRX) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 1.5 to 1.5 during a month. Analysts set a 12-month price target of $5.25 a share. The target implies a 381.65% spike from where the shares are currently trading. Also, the current price highlights a discount of 358.72% to analysts’ high consensus price target.Repros Therapeutics Inc. (NASDAQ:RPRX) Intraday Trading
The counter witnessed a trading volume of 0.11 million shares versus an average volume of 0.12 million shares during last trading session. Its last month’s stock price volatility remained 7.32% which for the week approaches 5.79%. The lowest price the stock reached in the last trading day was $1.06 and compares with the $1.02 52-week low. The stock recovered 12.37% since its low point and has performed -17.42% year-to-date.